Organon (OGN) Profit After Tax (2020 - 2026)
Organon (OGN) posted quarterly Profit After Tax of $108.0 million for Q2 2026, down 25.52% year-over-year from $145.0 million in Q2 2025, and down 26.03% on a QoQ basis from $146.0 million in Q1 2026.
Organon (OGN) Profit After Tax (2020 - 2026) Analysis & Trends
Organon has reported Profit After Tax for 7 years, with the latest figure at $108.0 million in Q2 2026.
- Profit After Tax for Q2 2026 came in at $108.0 million, down 25.52% year-over-year; the trailing twelve-month figure through Jun 2026 was $209.0 million (down 70.14% YoY), and the FY2025 annual result was $187.0 million, down 78.36% from the prior year.
- Profit After Tax eased to $108.0 million in Q2 2026, from $146.0 million in the prior quarter.
- Over five years, Profit After Tax peaked at $546.0 million in Q4 2023 and troughed at -$205.0 million in Q4 2025.
- A 5-year average of $180.3 million and a median of $168.5 million in 2023 frame the typical range for Profit After Tax.
- The widest annual swing landed in 2024, when Profit After Tax jumped 518.97%; it then plunged 288.07% in 2025.
- A 5-year view of Profit After Tax shows it stood at $108.0 million in 2022, then surged by 405.56% to $546.0 million in 2023, then sank by 80.04% to $109.0 million in 2024, then plunged by 288.07% to -$205.0 million in 2025, then surged by 152.68% to $108.0 million in 2026.
- Per Business Quant data, the three most recent Profit After Tax figures were $108.0 million in Q2 2026, $146.0 million in Q1 2026, and -$205.0 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 2.51 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 2.38 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.50 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -248.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 207.96 Mn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn | 108.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.00 Mn |
| Mar 31, 2026 | 146.00 Mn |
| Dec 31, 2025 | -205.00 Mn |
| Sep 30, 2025 | 160.00 Mn |
| Jun 30, 2025 | 145.00 Mn |
| Mar 31, 2025 | 87.00 Mn |
| Dec 31, 2024 | 109.00 Mn |
| Sep 30, 2024 | 359.00 Mn |
| Jun 30, 2024 | 195.00 Mn |
| Mar 31, 2024 | 201.00 Mn |
| Dec 31, 2023 | 546.00 Mn |
| Sep 30, 2023 | 58.00 Mn |
| Jun 30, 2023 | 242.00 Mn |
| Mar 31, 2023 | 177.00 Mn |
| Dec 31, 2022 | 108.00 Mn |
| Sep 30, 2022 | 227.00 Mn |
| Jun 30, 2022 | 234.00 Mn |
| Mar 31, 2022 | 348.00 Mn |
| Dec 31, 2021 | 202.00 Mn |
| Sep 30, 2021 | 323.00 Mn |